Osteoporosis, Postmenopausal Clinical Trial
Official title:
ZEST II for Osteoporotic Fracture Prevention
The goal of this study is to perform the first fracture reduction clinical trial with a potent antiresorptive agent (intravenous zoledronic acid) in the most vulnerable long-term care population.
Although close to 85% of frail women in long-term care (LTC) facilities have osteoporosis and the risk of osteoporotic fractures is nearly 10 times that of community dwelling elderly, few are treated and studies are scarce. It is postulated that in frail, LTC women an annual infusion of zoledronic acid, an antiresorptive therapy for osteoporosis, will: 1. be effective demonstrated by fracture reduction; 2. be safe. To address these hypotheses, up to 1000 female LTC residents age 65 and older will be screened in order to enroll 310 eligible for randomization in a 3 year, randomized, double-blind, calcium and vitamin D controlled trial with the antiresorptive agent zoledronic acid. Use of an intravenous, once yearly agent avoids concerns of oral bisphosphonate side effects, poor absorption and burden on staff. Participants will reside in the long-term care settings associated with the Division of Geriatric Medicine, University of Pittsburgh and will include women with multiple comorbid conditions, functional and cognitive impairment, and limited mobility. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03931109 -
Circulating miRNA in Primary Hyperparathyroidism
|
||
| Not yet recruiting |
NCT03232476 -
Effect of Mechanical Loading With PTH on Cortical Bone
|
Phase 4 | |
| Completed |
NCT02884401 -
Peri-implant Bone Changes in Post-menopausal Osteoporotic Women
|
N/A | |
| Completed |
NCT00073190 -
Patient- and Physician-Based Osteoporosis Education
|
Phase 1 | |
| Completed |
NCT00402441 -
Risedronate in the Prevention of Osteoporosis in Postmenopausal Women
|
Phase 4 | |
| Completed |
NCT03710889 -
Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption
|
Phase 3 | |
| Completed |
NCT00010712 -
Effects of Black Cohosh on Menopausal Hot Flashes
|
Phase 2 | |
| Recruiting |
NCT05058976 -
Romosozumab Use to Build Skeletal Integrity
|
Phase 4 | |
| Active, not recruiting |
NCT05405894 -
Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation
|
||
| Recruiting |
NCT03337971 -
Nutritional Supplement and Bone Health in Post-Menopausal Women
|
N/A | |
| Completed |
NCT03701113 -
Milk Protein and Bone Health in Postmenopausal Women
|
N/A | |
| Completed |
NCT01381588 -
The Prevalence of Osteoporotic Vertebral Compression Fractures (OVCF) in Korean Post Menopausal Women
|
N/A | |
| Completed |
NCT00383422 -
Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis
|
Phase 3 | |
| Completed |
NCT00549965 -
Satisfaction and Compliance of Risedronate in PMO
|
Phase 4 | |
| Completed |
NCT00035256 -
Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis
|
Phase 4 | |
| Completed |
NCT01386281 -
Julina Post-marketing Surveillance for Climacteric Symptoms in Japan
|
||
| Completed |
NCT05266261 -
Use of Ibandronate in Diabetic Patients
|
N/A | |
| Recruiting |
NCT04964388 -
Effect of GLP-1 Receptor Agonists on Trabecular Bone Score
|
Phase 2 | |
| Active, not recruiting |
NCT03623633 -
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
|
Phase 4 | |
| Recruiting |
NCT05575167 -
Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)
|